Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.48 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26785933 | 0.87 | MAPK1 (0.69) | MAPK1FLT3EGFRAURKBPDPK1 | |
| SCHEMBL26784629 | 0.83 | MAPK1 (0.71) | MAPK1FLT3EGFRAURKBPDPK1 | |
| SCHEMBL3260279 | 0.82 | MAPK1 (0.51) | MAPK1LMNASLC29A1FLT3PDPK1 | |
| SCHEMBL4693022 | 0.82 | FLT3 (0.66) | MAPK1LMNASLC29A1FLT3TTBK1 | |
| SCHEMBL23283445 | 0.78 | EGFR (0.76) | BRD4CSF1REGFRAURKBNT5C2 | |
| SCHEMBL6207398 | 0.78 | MAPK1 (0.47) | MAPK1FLT3EGFRAURKBPDPK1 | |
| SCHEMBL4690820 | 0.78 | LMNA (0.66) | MAPK1LMNASLC29A1FLT3PTK2 | |
| SCHEMBL6471191 | 0.77 | PDPK1 (0.62) | MAPK1LMNAFLT3PDPK1TTBK1 | |
| SCHEMBL4768894 | 0.77 | AURKA (0.57) | LMNAAURKBNPC1JAK2RAB9A | |
| SCHEMBL27873799 | 0.76 | ADORA3 (0.66) | MAPK1BRD4LMNAEGFRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633457-B2 | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use | BOISE STATE UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20200323960-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE | BOISE STATE UNIVERSITY | 2020-10-15 | — | — | US | disclosed |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-9550828-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150093391-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2015-04-02 | — | — | US | disclosed |
| US-8003101-B2 | Inflammatory mediator antagonists | GLAXOSMITHKLINE LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080044409-A1 | INFLAMMATORY MEDIATOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080019967-A1 | INFLAMMATORY MEDIATOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-7291332-B2 | Inflammatory mediator antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1849478-A2 | Inflammatory mediator antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-31 | — | — | EP | disclosed |
| EP-1071449-B1 | USE OF AN ANTAGONIST ANTIBODY TO THE INFLAMMATORY MEDIATOR ONCOSTATIN M (OSM) | GLAXO GROUP LTD (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-20060093602-A1 | Inflammatory mediator antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-05-04 | — | — | US | disclosed |
| US-20040081650-A1 | Inflammatory mediator antagonists | LIFE PAUL F (GB) | 2004-04-29 | — | — | US | disclosed |
| US-6706266-B1 | Oncostatin M antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-16 | — | — | US | disclosed |
| EP-1071449-A2 | ANTAGONISTS OF THE INFLAMMATORY MEDIATOR ONCOSTATIN M (OSM) | GLAXO GROUP LIMITED (GB) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999048523-A2 | ANTAGONISTS OF THE INFLAMMATORY MEDIATOR ONCOSTATIN M (OSM) | GLAXO GROUP LIMITED (GB) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | IL6, OGFRL1, OGFR | MAPK1 1184/4885BRD4 2718/4885LMNA 3338/4885 |
| US-20150093391-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | IL6, OGFRL1, OGFR | MAPK1 1184/4885BRD4 2718/4885LMNA 3338/4885 |
| US-20200323960-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE | OGFR, OGFRL1, ELAVL1 | MAPK1 1380/4885BRD4 2985/4885LMNA 2391/4885 |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | IL6, OGFRL1, OGFR | MAPK1 1184/4885BRD4 2718/4885LMNA 3338/4885 |
| US-11633457-B2 | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use | OGFR, OGFRL1, ELAVL1 | MAPK1 1380/4885BRD4 2985/4885LMNA 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.